AU2012243289A1 - Prostate cancer therapy with Hsp90 inhibitory compounds - Google Patents

Prostate cancer therapy with Hsp90 inhibitory compounds Download PDF

Info

Publication number
AU2012243289A1
AU2012243289A1 AU2012243289A AU2012243289A AU2012243289A1 AU 2012243289 A1 AU2012243289 A1 AU 2012243289A1 AU 2012243289 A AU2012243289 A AU 2012243289A AU 2012243289 A AU2012243289 A AU 2012243289A AU 2012243289 A1 AU2012243289 A1 AU 2012243289A1
Authority
AU
Australia
Prior art keywords
optionally substituted
indol
triazole
phenyl
dihydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012243289A
Other languages
English (en)
Inventor
Suqin HE
David Proia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Synta Phamaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Phamaceuticals Corp filed Critical Synta Phamaceuticals Corp
Publication of AU2012243289A1 publication Critical patent/AU2012243289A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012243289A 2011-02-24 2012-02-23 Prostate cancer therapy with Hsp90 inhibitory compounds Abandoned AU2012243289A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161446099P 2011-02-24 2011-02-24
US61/446,099 2011-02-24
US201161491531P 2011-05-31 2011-05-31
US61/491,531 2011-05-31
PCT/US2012/026268 WO2012141796A2 (en) 2011-02-24 2012-02-23 Prostate cancer therapy with hsp90 inhibitory compounds

Publications (1)

Publication Number Publication Date
AU2012243289A1 true AU2012243289A1 (en) 2013-08-29

Family

ID=46614578

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012243289A Abandoned AU2012243289A1 (en) 2011-02-24 2012-02-23 Prostate cancer therapy with Hsp90 inhibitory compounds

Country Status (7)

Country Link
US (1) US20140051665A1 (OSRAM)
EP (1) EP2678014A2 (OSRAM)
JP (1) JP2014507443A (OSRAM)
CN (1) CN103391779A (OSRAM)
AU (1) AU2012243289A1 (OSRAM)
CA (1) CA2827739A1 (OSRAM)
WO (1) WO2012141796A2 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2035396T3 (pl) 2006-05-25 2014-10-31 Synta Pharmaceuticals Corp Związki triazolowe modulujące aktywność hsp90
WO2009148599A1 (en) 2008-06-04 2009-12-10 Synta Pharmaceuticals Corp. Pyrrole compunds that modulate hsp90 activity
EP2323737A2 (en) 2008-08-08 2011-05-25 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2010017479A1 (en) * 2008-08-08 2010-02-11 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CA2787785C (en) 2010-01-28 2018-03-06 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
WO2012154967A1 (en) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators
CA2840986A1 (en) 2011-07-07 2013-01-10 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
US20140286902A1 (en) 2011-11-02 2014-09-25 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
CA2854188A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
DK3179991T3 (da) 2014-08-11 2021-12-06 Acerta Pharma Bv Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
DK3179992T3 (da) 2014-08-11 2022-07-11 Acerta Pharma Bv Terapeutisk kombination af en btk-inhibitor, en pd-1-inhibitor og/eller en pd-l1-inhibitor
CN111164093A (zh) * 2017-09-27 2020-05-15 塔尔格免疫治疗有限公司 去势抵抗性前列腺癌

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
PT1817295E (pt) * 2004-11-18 2013-02-18 Synta Pharmaceuticals Corp Compostos de triazol que modulam a actividade da hsp90
AU2008287367B2 (en) * 2007-08-13 2012-02-23 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US20130171105A1 (en) * 2010-05-24 2013-07-04 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
WO2012116061A1 (en) * 2011-02-23 2012-08-30 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with radiotherapy

Also Published As

Publication number Publication date
CN103391779A (zh) 2013-11-13
WO2012141796A2 (en) 2012-10-18
CA2827739A1 (en) 2012-10-18
EP2678014A2 (en) 2014-01-01
WO2012141796A3 (en) 2012-12-27
JP2014507443A (ja) 2014-03-27
US20140051665A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
AU2012243289A1 (en) Prostate cancer therapy with Hsp90 inhibitory compounds
US10500193B2 (en) Combination therapy of HSP90 inhibitors with platinum-containing agents
EP2849751A1 (en) Treating cancer with hsp90 inhibitory compounds
US20140045908A1 (en) Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
AU2011302344B2 (en) HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients
US8906885B2 (en) Treating cancer with HSP90 inhibitory compounds
US20170340652A1 (en) Combination therapy of hsp90 inhibitory compounds with chk inhibitors
US20140255348A1 (en) Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
EP2714039A1 (en) Combination therapy of hsp90 inhibitory compounds with mek inhibitors
US20130171105A1 (en) Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
AU2012339679A1 (en) Combination therapy of Hsp90 inhibitors with BRAF inhibitors
EP2714038A1 (en) Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application